Busque Philippe, Senior Vice President of Global Sales and Services, has demonstrated a consistent pattern of selling activity in Cytek Biosciences, Inc. (CTKB) shares, with no recorded purchases across 24 transactions filed with the SEC. The transactions, spanning from March 2024 through March 2026, reveal a series of sales executed under code "F" (indicating transactions made to cover tax obligations), totaling $49,220.56 in aggregate value. The largest single sale occurred on March 20, 2024, with shares worth $14,264.30 disposed, followed by smaller periodic sales typically ranging between $2,000 and $6,300 per transaction. Notably, all sales were structured in clusters of three per filing date—such as the March 10, 2026 disposals valued at $6,328.08, $3,857.76, and $2,686.05—suggesting systematic liquidation tied to equity compensation events.
Philippe’s activity is exclusively concentrated in CTKB, with no trades in other securities. The absence of buy transactions and the repeated pattern of tax-related sales indicate these disposals are likely tied to vesting schedules rather than discretionary trading. While the dollar amounts are modest relative to typical executive transactions, the consistency in timing—with sales occurring roughly every quarter—points to a predetermined plan. The most recent activity, in March 2026, follows the same structure as prior years, reinforcing a non-discretionary approach. No open-market sales (code "S") appear in the filings, further narrowing the scope to compensation-related adjustments rather than active portfolio management.
AI-assisted summary